Legaspi, Hannilore V.

HRN: 04-64-39  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/06/2022
CEFUROXIME 1.5GM (VIAL)
06/06/2022
06/07/2022
IV
1.5g
Q8 X 3 Doses
S/P NSVD With Episiorrhaphy Of 4th Degree Laceration
Waiting Final Action 
06/06/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/06/2022
06/07/2022
IV
500mg
Q8h X 3 Doses
S/P NSVD With Episiorrhaphy Of 4th Degree Laceration
Waiting Final Action 
07/28/2023
CEFUROXIME 1.5GM (VIAL)
07/29/2023
07/29/2023
IV
1.5gm
LD
D And C
Waiting Final Action 
07/28/2023
CEFUROXIME 1.5GM (VIAL)
07/28/2023
07/29/2023
IV
1.5gm
Q8 X 3 Doses
Post OP Prophylaxis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: